← SynDRA
SOLRIAMFETOL
SynDRA canonical compound SYN0039713 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx |
|---|
| Primary target(s) | SLC6A2 | SLC6A3 |
|---|
| Mechanism of action | dopamine reuptake inhibitor |
|---|
| Indication | narcolepsy |
|---|
| Disease area | neurology/psychiatry |
|---|
All known targets
Mechanisms of action (all sources)
- dopamine reuptake inhibitor
ATC classes
- N06B · PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS
Cross-references
Synonyms
- sunosi
- JZP-110
- ADX-N05
- ARL-N05
- SKL-N05
- ADX-N-05
- R-228060
- SKL-N-05
- YKP-10A
- Benzenepropanol, beta-amino-, 1-carbamate, (betaR)-
- (2R)-2-amino-3-phenylpropyl carbamate
- Sunosi
- YKP 10A
- JZP 110
- R 228060
- Benzenepropanol, beta-amino-, carbamate (ester), (betaR)-
- [(2R)-2-amino-3-phenylpropyl] carbamate
- Benzenepropanol, beta-amino-, carbamate (ester), (R)-
- ((2R)-2-amino-3-phenylpropyl) carbamate
- solriamfetolum
- RefChem:57009
- N06BA14
- DTXCID401513492
- (R)-2-amino-3-phenylpropyl carbamate
- Solriamfetol [USAN]
- Adx-N05 free base
- (R)-2-amino-3-phenylpropylcarbamate
- UNII-939U7C91AI
- MFCD30481303
- Solriamfetol (USAN)
- (2R)-2-Amino-3-phenylpropyl Carbamate; JZP 110
- ADX N05
- SOLRIAMFETOL [MI]
- SOLRIAMFETOL [INN]
- ADXN05
- SOLRIAMFETOL [WHO-DD]
- JZP110
- O-Carbamoyl-(D)-phenylalaninol
Reported adverse events
- Abdominal pain
- Chest discomfort
- Dizziness
- Dry mouth
- Feeling jittery
- Headache
- Hyperhidrosis
- Hypersensitivity
- Insomnia
- Irritability
- Nausea
- Palpitations
Look up SOLRIAMFETOL in the interactive SynDRA portal →